GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anthera Pharmaceuticals, Inc. (ANTH) [hlAlert]

Rating:
Outperform
ANTH
up 32.92 %

Anthera Pharmaceuticals, Inc. (ANTH) rated Outperform by Leerink Swann

Posted on: Tuesday,  Nov 13, 2012  10:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) on 11/13/2012, when the stock price was $5.68.
Since then, Anthera Pharmaceuticals, Inc. has gained 32.92% as of 01/13/2016's recent price of $7.55.
If you would have followed this Leerink Swann 's recommendation on ANTH, you would have gained 32.92% of your investment in 1156 days.

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/13/2012 10:25 AM Buy
None
5.68
as of 12/31/2012
1 Week down  -3.12 %
1 Month down  -3.12 %
3 Months down  -12.67 %
1 YTD down  -12.67 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy